OMER

Rating neutralAI Memo

Omeros

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

YARTEMLEA CMS NTAP reimbursement • 2026-10-01

Base target: $21 / p=50% prob

Biggest risk

The business remains concentrated in a recently launched product, while the EMA negative opinion creates regulatory uncertainty. Broader indications and pipeline programs remain development-stage. Recent officer and director Form 4 sales add a modest sentiment overhang but are not operating evidence. [#SEC-FORM4-2026-09-01]

Invalidation

Break below $10 or thesis failure.

What would change my mind?

Strong early YARTEMLEA uptake, positive operating cash flow, debt reduction and CMS reimbursement support could improve the commercial trajectory. EMA re-examination and pipeline enrollment provide additional upside optionality. [#SEC-8K-2026-08-12]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-02

Base target

$21

p=50%

Bull target

$38

p=25%

Bear target

$10

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

YARTEMLEA commercial ramp
Pipeline enrollment milestones
Zaltenibart Phase 3 progression

BearKey bullets

EMA re-examination may fail or be delayed after the negative CHMP opinion.
Pipeline milestones depend on clinical, regulatory and execution outcomes, with no firm timing for several programs.
Recent Form 4 filings record open-market sales by multiple officers and directors.

WatchKey bullets

YARTEMLEA CMS NTAP reimbursement

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $21 (p=50%)

Target spread vs base: +81% / -52%

Scenario probabilities

Bull Target: $38 (p=25%)Base Target: $21 (p=50%)Bear Target: $10 (p=25%)

Commentary

Headline tone is constructive after Q2 YARTEMLEA sales, CMS support and capital-structure actions, but the EMA setback offsets part of the upside. The packet does not confirm persistent post-release price reaction, analyst revisions or target changes; social, options, short-interest and employee sentiment data are unavailable. This remains a monitoring setup rather than a high-conviction bullish call.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

YARTEMLEA commercial ramp
Pipeline enrollment milestones
Zaltenibart Phase 3 progression

Scenarios

Bull Target (Scenario probability)

$38 / p=25% prob

Base Target (Scenario probability)

$21 / p=50% prob

Bear Target (Scenario probability)

$10 / p=25% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.50

Events

Other notable items detected

EVENT2026-10-01
YARTEMLEA CMS NTAP reimbursement
CMS granted YARTEMLEA New Technology Add-on Payment status effective October 1, 2026, supporting eligible hospital reimbursement and patient access. [#SEC-8K-2026-08-12]
Prob 75.00% • Move 10.00% • Priced-in 60.00%
EVENT2026-11-23
EMA narsoplimab re-examination
The EMA CHMP issued a negative opinion on the TA-TMA application, while Omeros requested re-examination with external expert review. A favorable outcome would expand geographic opportunity; delay or rejection remains material downside risk. [#SEC-8K-2026-08-12]
Prob 40.00% • Move 22.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

YARTEMLEA commercial ramp
2026-12-01
Q2 gross YARTEMLEA revenue reached $32.2 million, up 190% quarter over quarter, with $28.5 million net revenue and $4.1 million of operating cash flow. Adjusted net income was $1.8 million, though reported GAAP results included non-cash derivative gains. [Omeros Q2 release](https://s21.q4cdn.com/975996899/files/doc_news/Omeros-Corporation-Reports-Second-Quarter-2026-Financial-Results-2026.pdf) [#SEC-8K-2026-08-12]
Prob 80% • Move 12% • Priced-in 70%

Long-term Catalysts

Months to a year

Pipeline enrollment milestones
2026-12-31
Omeros expects by year-end 2026 to begin enrollment in YARTEMLEA studies for hyperinflammatory ARDS and pediatric TA-TMA, and to begin an inpatient OMS527 study after additional FDA-requested nonclinical work. [#SEC-8K-2026-08-12]
Prob 55% • Move 15% • Priced-in 35%
Zaltenibart Phase 3 progression
2027-09-02
Management said work with Novo Nordisk on the MASP-3 inhibitor zaltenibart remained on track toward Phase 3 initiation, but no firm date or economics were provided. [#SEC-8K-2026-08-12]
Prob 45% • Move 12% • Priced-in 30%

Risks

EMA re-examination may fail or be delayed after the negative CHMP opinion.
Pipeline milestones depend on clinical, regulatory and execution outcomes, with no firm timing for several programs.
Recent Form 4 filings record open-market sales by multiple officers and directors. [#SEC-FORM4-2026-09-01]
Reported GAAP profitability benefited from non-cash derivative gains; underlying earnings remain modest.
YARTEMLEA adoption, reimbursement realization and sales durability remain unproven beyond the initial commercial ramp.

Peers

Symbol	Summary
CRVS	Closest size-matched same-sector reference in the packet, but operating and commercial comparability to OMER is limited.
IMTX	Similar market-cap biotechnology reference; valuation remains milestone-driven and not directly comparable.
GILD	Large-cap biopharma commercialization benchmark rather than a direct valuation peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

CRVS

Closest size-matched same-sector reference in the packet, but operating and commercial comparability to OMER is limited.

IMTX

Similar market-cap biotechnology reference; valuation remains milestone-driven and not directly comparable.

GILD

Large-cap biopharma commercialization benchmark rather than a direct valuation peer.